Amoy Diagnostics
AmoyDx, AstraZeneca Partner on HER2 Lung Cancer CDx Development in China
Amoy will develop a companion diagnostic for Enhertu (trastuzumab deruxtecan) under its latest agreement to develop companion diagnostics for AstraZeneca's therapies.
Amoy Diagnostics, AstraZeneca Partner to Advance PARP Inhibitor CDx For Maintenance Indication
AmoyDx's test, if approved, would identify patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer who are eligible for maintenance treatment.
Amoy Diagnostics PLC Panel Gets Approval in Japan as CDx for Retevmo in Non-Small Cell Lung Cancer
Oncologists in Japan can now use the AmoyDx Pan Lung Cancer PCR Panel to identify patients with RET fusions that make them eligible for treatment with the Eli Lilly drug.
Alercell to Distribute Amoy Diagnostic Ros1 Gene Fusion Detection Kit in US
The 14-fusion PCR assay for lung cancer subtyping is available for research-use only but will be more broadly distributed when the kits gain FDA clearance.
In Brief This Week: Labcorp, QuantuMDx, LumiraDx, Danaher, Thermo Fisher Scientific, and More
News items for the in vitro diagnostics industry for the week of Feb. 21, 2022.
Nov 25, 2019
AmoyDx, Eisai Form CDx Development Alliance
Oct 12, 2018
AmoyDx Lung Cancer CDx Approved in South Korea
Jan 29, 2018
AmoyDx, Medikonia Ink MDx Distribution Deal
May 16, 2017